Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group.

J Infect Dis. 1999 Mar;179(3):590-9. Unique Identifier : AIDSLINE MED/99137794
Shaffer N; Roongpisuthipong A; Siriwasin W; Chotpitayasunondh T; Chearskul S; Young NL; Parekh B; Mock PA; Bhadrakom C; Chinayon P; Kalish ML; Phillips SK; Granade TC; Subbarao S; Weniger BG; Mastro TD; Centers for Disease Control and Prevention, Atlanta, GA 30333,; USA. nas4@cdc.gov

Abstract: To determine the rate and risk factors for human immunodeficiency virus (HIV)-1 subtype E perinatal transmission, with focus on virus load, pregnant HIV-infected women and their formula-fed infants were followed prospectively in Bangkok. Of 281 infants with known outcome, 68 were infected (transmission rate, 24.2%; 95% confidence interval, 19.3%-29.6%). Transmitting mothers had a 4.3-fold higher median plasma HIV RNA level at delivery than did nontransmitters (P<.001). No transmission occurred at <2000 copies/mL. On multivariate analysis, prematurity (adjusted odds ratio [AOR], 4.5), vaginal delivery (AOR, 2.9), low NK cell percentage (AOR, 2.4), and maternal virus load were associated with transmission. As RNA quintiles increased, the AOR for transmission increased linearly from 4.5 to 24.8. Two-thirds of transmission was attributed to virus load>10,000 copies/mL. Although risk is multifactorial, high maternal virus load at delivery strongly predicts transmission. This may have important implications for interventions designed to reduce perinatal transmission.

Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY/*TRANSMISSION Adult Confidence Intervals CD4 Lymphocyte Count Delivery Disease Transmission, Vertical/*STATISTICS & NUMER DATA Female Gestational Age Human HIV Seropositivity/BLOOD/EPIDEMIOLOGY/*TRANSMISSION HIV-1/CLASSIFICATION/*ISOLATION & PURIF Immunophenotyping Infant Infant, Newborn Killer Cells, Natural/IMMUNOLOGY Lymphocytes/IMMUNOLOGY Odds Ratio Pregnancy Pregnancy Complications, Infectious/BLOOD/EPIDEMIOLOGY/*VIROLOGY Risk Factors Risk-Taking Support, U.S. Gov't, P.H.S. Thailand/EPIDEMIOLOGY *Viral Load
990630
A9960913

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .